What is MediWound?
Founded in 2001 and headquartered in Israel, MediWound operates as a fully integrated biopharmaceutical company. The firm is primarily recognized for its patented proteolytic enzyme technology, which serves as the foundation for a suite of novel therapeutics designed to treat severe burns, chronic wounds, and other hard-to-heal conditions. By maintaining an integrated model that spans development, manufacturing, and commercialization, MediWound occupies a unique niche in the regenerative medicine and wound care sectors.
The company's market position is bolstered by its ability to address significant unmet clinical needs, providing high-value solutions that improve patient outcomes in both civilian and specialized medical environments. Its focus on enzymatic debridement and advanced wound healing positions it as a key player in the global biopharma landscape.
How much funding has MediWound raised?
MediWound has raised a total of $85.7M across 3 funding rounds:
Stock Offering
$70M
Unspecified
$9M
Other Financing Round
$6.7M
Stock Issuance/Offering (2014): $70M, investors not publicly disclosed
Unspecified (2022): $9M led by Biomedical Advanced Research and Development Authority (BARDA
Other Financing Round (2023): $6.7M supported by U.S. Department of Defense
Key Investors in MediWound
U.S. Department of Defense
The U.S. Department of Defense is the federal executive department responsible for national security and the oversight of advanced military and medical technology development.
Biomedical Advanced Research and Development Authority (BARDA)
BARDA is a federal agency focused on the advanced research and development of medical countermeasures to address public health threats and emergency preparedness.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MediWound?
With the recent influx of capital, MediWound is well-positioned to accelerate its research and development initiatives, particularly those aligned with national security and public health priorities. The strategic alignment with government agencies suggests a focus on scaling production and expanding the reach of its therapeutic portfolio into broader clinical applications.
Future growth will likely center on the commercial expansion of its core technologies and the potential for new therapeutic indications. As the company navigates the complexities of the biopharmaceutical market, the focus remains on maintaining its competitive edge through rigorous clinical validation and the continued optimization of its proprietary enzyme-based platforms.
